Nirmatrelvir/ritonavir was recently granted emergency use authorization for mild to moderate coronavirus disease 2019. Drug-drug interactions between ritonavir and tacrolimus are underappreciated by nontransplant providers. We describe 2 solid organ transplant recipients prescribed nirmatrelvir/ritonavir for outpatient use who developed tacrolimus toxicity requiring hospitalization and were managed with rifampin for toxicity reversal.
Keywords: COVID-19; drug interactions; nirmatrelvir/ritonavir; tacrolimus.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.